Chardan Capital Has Bullish Outlook for ABUS FY2025 Earnings
Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) – Equities researchers at Chardan Capital lifted their FY2025 earnings per share estimates for shares of Arbutus Biopharma in a report released on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will post earnings of ($0.30) per share for the year, up […]
Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) – Equities researchers at Chardan Capital lifted their FY2025 earnings per share estimates for shares of Arbutus Biopharma in a report released on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will post earnings of ($0.30) per share for the year, up […]
